BlackRock, Inc. 13D and 13G filings for Atossa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
BlackRock Inc. BLK |
9,667,615 7.700% |
0 (Unchanged) |
Filing |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
BlackRock Inc. BLK |
9,667,615 7.700% |
6,078,932 (+169.39%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Atossa Therapeutics, Inc. ATOS |
BlackRock Inc. BLK |
3,588,683 2.800% |
-5,950,910 (-62.38%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
BlackRock Inc. BLK |
9,539,593 7.500% |
9,539,593 (New Position) |
Filing |